US Stock MarketDetailed Quotes
MDNAF Medicenna Therapeutics
- 1.590
- +0.030+1.92%
15min DelayClose Aug 23 16:00 ET
121.53MMarket Cap-9408P/E (TTM)
1.630High1.550Low43.93KVolume1.550Open1.560Pre Close69.98KTurnover0.20%Turnover RatioLossP/E (Static)76.43MShares2.20052wk High8.88P/B35.61MFloat Cap0.15152wk Low--Dividend TTM22.40MShs Float6.840Historical High--Div YieldTTM5.13%Amplitude0.151Historical Low1.593Avg Price1Lot Size
About Medicenna Therapeutics Company
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
Company Profile
SymbolMDNAF
Company NameMedicenna Therapeutics
Founded2015
CEODr. Fahar Merchant,PhD
MarketPink Market
Employees19
Fiscal Year Ends03-31
Address2 Bloor Street West,7th floor
CityToronto
ProvinceOntario
CountryCanada
Zip CodeM4W 3E2
Phone1-416-648-5555
Websitehttp://www.medicenna.com
Company Executives
- Name
- Position
- Salary
- Dr. Fahar Merchant,PhD
- President, Chief Executive Officer and Chairman of the Board
- 877.19K
- Rosemina Merchant
- Chief Development Officer
- 613.71K
- David Hyman
- Chief Financial Officer
- --
- Dr. John Geltosky, PhD
- Independent Director
- 117.45K
- Dr. John H. Sampson, M.B.A.,M.D.,PhD
- Independent Director
- 111.83K
- Albert Beraldo, C.A.,C.P.A.
- Lead Independent Director
- 142.95K
- Karen A. Dawes, M.A.
- Independent Director
- 123.70K
- Karim Lalji
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg